These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7678439)

  • 21. New medication for the treatment of benign prostatic hyperplasia.
    Miller CA
    Geriatr Nurs; 1993; 14(2):111-2. PubMed ID: 7681420
    [No Abstract]   [Full Text] [Related]  

  • 22. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia.
    Guess HA; Heyse JF; Gormley GJ
    Prostate; 1993; 22(1):31-7. PubMed ID: 7678930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia.
    Beisland HO; Binkowitz B; Brekkan E; Ekman P; Kontturi M; Lehtonen T; Lundmo P; Pappas F; Round E; Shapiro D
    Eur Urol; 1992; 22(4):271-7. PubMed ID: 1283370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
    McConnell JD; Wilson JD; George FW; Geller J; Pappas F; Stoner E
    J Clin Endocrinol Metab; 1992 Mar; 74(3):505-8. PubMed ID: 1371291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Finasteride for benign prostatic hyperplasia.
    Blumenstein BA
    N Engl J Med; 1993 Feb; 328(6):443. PubMed ID: 7678438
    [No Abstract]   [Full Text] [Related]  

  • 26. The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia.
    Tempany CM; Partin AW; Zerhouni EA; Zinreich SJ; Walsh PC
    Prostate; 1993; 22(1):39-42. PubMed ID: 7678931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimism expressed over prostate drug.
    Jenks S
    J Natl Cancer Inst; 1991 Dec; 83(23):1712-3. PubMed ID: 1722823
    [No Abstract]   [Full Text] [Related]  

  • 28. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group.
    Stoner E
    J Urol; 1992 May; 147(5):1298-302. PubMed ID: 1373779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hormonal effects of a 5 alpha-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia.
    Vermeulen A; Giagulli VA; De Schepper P; Buntinx A
    Eur Urol; 1991; 20 Suppl 1():82-6. PubMed ID: 1722168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changing attitudes in the treatment of benign prostatic hyperplasia: the role of 5 alpha-reductase inhibition. Proceedings of two symposia: Nice, France, November 11, 1989 and Amsterdam, The Netherlands, June 14, 1990.
    Eur Urol; 1991; 20 Suppl 1():1-86. PubMed ID: 1722153
    [No Abstract]   [Full Text] [Related]  

  • 31. [The treatment of patients with benign prostatic hyperplasia with Proscar MSD (finasteride)].
    Stepanov VN; Teodorovich OV; Seregin AV; Kadyrov ZA
    Urol Nefrol (Mosk); 1995; (5):28-30. PubMed ID: 8571480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transurethral resection of the prostate: still the gold standard?
    Ramsey EW
    Can J Surg; 1993 Feb; 36(1):9-10. PubMed ID: 7680274
    [No Abstract]   [Full Text] [Related]  

  • 33. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H; Lan O; Poulain JE; Comenducci A
    Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1992 Sep; 268(11):1390. PubMed ID: 1380995
    [No Abstract]   [Full Text] [Related]  

  • 35. Testosterone levels in benign prostatic hyperplasia: sexual function and response to therapy with dutasteride.
    Swerdloff R
    Nat Clin Pract Urol; 2006 Oct; 3(10):528-9. PubMed ID: 17031376
    [No Abstract]   [Full Text] [Related]  

  • 36. Dutasteride (Avodart) for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 2002 Dec; 44(1146):109-10. PubMed ID: 12500154
    [No Abstract]   [Full Text] [Related]  

  • 37. Chemoprevention strategies for prostate cancer: the role of 5 alpha-reductase inhibitors.
    Gormley GJ
    J Cell Biochem Suppl; 1992; 16H():113-7. PubMed ID: 1283894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is it worth the wait?
    Wyllie MG
    BJU Int; 2009 Jul; 104(1):121-2. PubMed ID: 19646125
    [No Abstract]   [Full Text] [Related]  

  • 39. [Therapy of benign prostatic hyperplasia: terazosin or finasteride?].
    Trinkler FB
    Praxis (Bern 1994); 1997 Aug; 86(34):1305-6. PubMed ID: 9381019
    [No Abstract]   [Full Text] [Related]  

  • 40. Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolism.
    Matzkin H; Chen J; Weisman Y; Goldray D; Pappas F; Jaccard N; Braf Z
    Clin Endocrinol (Oxf); 1992 Nov; 37(5):432-6. PubMed ID: 1283117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.